1
|
Olsen SC, Boggiatto PM, Nol P, McCollum MP, Rhyan JC. Immune Responses and Efficacy of Brucella Abortus Strain RB51 in Bison After Delivery in a Dry Dart Formulation or by Parenteral Inoculation. Front Vet Sci 2021; 8:706160. [PMID: 34395578 PMCID: PMC8363076 DOI: 10.3389/fvets.2021.706160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Accepted: 07/05/2021] [Indexed: 11/22/2022] Open
Abstract
Bison (Bison bison) heifer calves (n = 32) were randomly assigned to control or vaccination with 1010 colony-forming units of Brucella abortus strain RB51 (RB51) vaccine by single or boostered parenteral delivery, or by surgical implantation of a dry dart formulation (n = 8/trt). Serum and/or peripheral blood mononuclear cells (PBMC) were obtained at 0, 4, 8, 13, 16, 21, and 24 wks after initial vaccination and at 0, 4, 8, 12, 15, 22, and 27 wks after booster vaccination to characterize humoral and cellular immune responses to RB51. Bison in both RB51 vaccination treatments demonstrated greater (P < 0.0001) serum humoral responses when compared to non-vaccinates, with parenteral vaccinates demonstrating greater (P < 0.01) responses when compared to mean responses of bison inoculated with the dry dart. Only the booster vaccinated treatment demonstrated greater (P < 0.0001) humoral responses than control bison in samples collected after re-inoculation. At 4, 8, 12, 16, and 24 wks after initial vaccination, PBMC from parenteral RB51 vaccinates demonstrated greater proliferative responses to RB51 when compared to responses of control animals. In comparison, bison inoculated with the RB51 dry dart did not demonstrate greater (P > 0.05) proliferative responses when compared to responses of non-vaccinates. Bison were pasture bred and pregnant animals experimentally challenged in mid-gestation with 107 CFU of B. abortus strain 2,308. Bison in parenteral vaccination treatments had reduced (P < 0.05) abortions and infection in uterine and fetal samples as compared to non-vaccinated bison, with booster vaccinates tending to have the lowest colonization (CFU/gm) in tissues. In comparison, the dry dart formulation did reduce abortion (P < 0.05) but not infection (P > 0.05) in most tissues when compared to non-vaccinated bison. The results of this study reaffirm the efficacy of boostered parenteral vaccination of bison with RB51 in preventing brucellosis. Our data also suggests that the novel dry dart RB51 formulation does not induce sufficient efficacy in bison after a single inoculation.
Collapse
Affiliation(s)
- Steven C Olsen
- Department of Agriculture, Infectious Bacterial Diseases of Livestock Research Unit, National Animal Disease Center, Agricultural Research Service, Ames, IA, United States
| | - Paola M Boggiatto
- Department of Agriculture, Infectious Bacterial Diseases of Livestock Research Unit, National Animal Disease Center, Agricultural Research Service, Ames, IA, United States
| | - Pauline Nol
- Wildlife Health Program, Colorado Division of Parks and Wildlife, Denver, CO, United States
| | - Matthew P McCollum
- Animal Reproduction and Biotechnology Lab, Colorado State University, Fort Collins, CO, United States
| | - Jack C Rhyan
- Independent Consultant, Fort Collins, CO, United States
| |
Collapse
|
2
|
Hampton JO, Arnemo JM, Barnsley R, Cattet M, Daoust PY, DeNicola AJ, Eccles G, Fletcher D, Hinds LA, Hunt R, Portas T, Stokke S, Warburton B, Wimpenny C. Animal welfare testing for shooting and darting free-ranging wildlife: a review and recommendations. WILDLIFE RESEARCH 2021. [DOI: 10.1071/wr20107] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Several important techniques for managing wildlife rely on ballistics (the behaviour of projectiles), including killing techniques (shooting) as well as capture and marking methods (darting). Because all ballistic techniques have the capacity to harm animals, animal welfare is an important consideration. Standardised testing approaches that have allowed refinement for other physical killing and capture methods (e.g. traps for mammals) have not been applied broadly to ballistic methods. At the same time, new technology is becoming available for shooting (e.g. subsonic and lead-free ammunition) and darting (e.g. dye-marker darts). We present several case studies demonstrating (a) how basic ballistic testing can be performed for novel firearms and/or projectiles, (b) the benefits of identifying methods producing undesirable results before operational use, and (c) the welfare risks associated with bypassing testing of a technique before broad-scale application. Following the approach that has been used internationally to test kill-traps, we suggest the following four-step testing process: (1) range and field testing to confirm accuracy and precision, the delivery of appropriate kinetic energy levels and projectile behaviour, (2) post-mortem assessment of ballistic injury in cadavers, (3) small-scale live animal pilot studies with predetermined threshold pass/fail levels, and (4) broad-scale use with reporting of the frequency of adverse animal welfare outcomes. We present this as a practical approach for maintaining and improving animal welfare standards when considering the use of ballistic technology for wildlife management.
Collapse
|
3
|
Lalsiamthara J, Lee JH. Development and trial of vaccines against Brucella. J Vet Sci 2017; 18:281-290. [PMID: 28859268 PMCID: PMC5583415 DOI: 10.4142/jvs.2017.18.s1.281] [Citation(s) in RCA: 62] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2017] [Revised: 07/07/2017] [Accepted: 07/14/2017] [Indexed: 01/18/2023] Open
Abstract
The search for ideal brucellosis vaccines remains active today. Currently, no licensed human or canine anti-brucellosis vaccines are available. In bovines, the most successful vaccine (S19) is only used in calves, as adult vaccination results in orchitis in male, prolonged infection, and possible abortion complications in pregnant female cattle. Another widely deployed vaccine (RB51) has a low protective efficacy. An ideal vaccine should exhibit a safe profile as well as enhance protective efficacy. However, currently available vaccines exhibit one or more major drawbacks. Smooth live attenuated vaccines suffer shortcomings such as residual virulence and serodiagnostic interference. Inactivated vaccines, in general, confer relatively low levels of protection. Recent developments to improve brucellosis vaccines include generation of knockout mutants by targeting genes involved in metabolism, virulence, and the lipopolysaccharide synthesis pathway, as well as generation of DNA vaccines, mucosal vaccines, and live vectored vaccines, have all produced varying degrees of success. Herein, we briefly review the bacteriology, pathogenesis, immunological implications, candidate vaccines, vaccinations, and models related to Brucella.
Collapse
Affiliation(s)
| | - John Hwa Lee
- College of Veterinary Medicine, Chonbuk National University, Iksan 54596, Korea
| |
Collapse
|
4
|
Waters WR, Palmer MV. Mycobacterium bovis Infection of Cattle and White-Tailed Deer: Translational Research of Relevance to Human Tuberculosis. ILAR J 2016; 56:26-43. [PMID: 25991696 DOI: 10.1093/ilar/ilv001] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Tuberculosis (TB) is a premier example of a disease complex with pathogens primarily affecting humans (i.e., Mycobacterium tuberculosis) or livestock and wildlife (i.e., Mycobacterium bovis) and with a long history of inclusive collaborations between physicians and veterinarians. Advances in the study of bovine TB have been applied to human TB, and vice versa. For instance, landmark discoveries on the use of Koch's tuberculin and interferon-γ release assays for diagnostic purposes, as well as Calmette and Guérin's attenuated M. bovis strain as a vaccine, were first evaluated in cattle for control of bovine TB prior to wide-scale use in humans. Likewise, recent discoveries on the role of effector/memory T cell subsets and polyfunctional T cells in the immune response to human TB, particularly as related to vaccine efficacy, have paved the way for similar studies in cattle. Over the past 15 years, substantial funding for development of human TB vaccines has led to the emergence of multiple promising candidates now in human clinical trials. Several of these vaccines are being tested for immunogenicity and efficacy in cattle. Also, the development of population-based vaccination strategies for control of M. bovis infection in wildlife reservoirs will undoubtedly have an impact on our understanding of herd immunity with relevance to the control of both bovine and human TB in regions of the world with high prevalence of TB. Thus, the one-health approach to research on TB is mutually beneficial for our understanding and control of TB in humans, livestock, and wildlife.
Collapse
Affiliation(s)
- W Ray Waters
- Dr. W. Ray Waters, DVM, PhD, is a veterinary medical officer in the TB Research Project in the Infectious Bacterial Diseases of Livestock Research Unit at the National Animal Disease Center, Agricultural Research Service, United States Department of Agriculture (USDA), Ames, Iowa, and a collaborator/assistant professor of veterinary microbiology and preventive medicine at Iowa State University, Ames, Iowa. Dr. Mitchell V. Palmer, DVM, PhD, is a veterinary medical officer in the TB Research Project in the Infectious Bacterial Diseases of Livestock Research Unit at the National Animal Disease Center, Agricultural Research Service, USDA, Ames, Iowa, and a collaborator/assistant professor of veterinary pathology at Iowa State University, Ames, Iowa
| | - Mitchell V Palmer
- Dr. W. Ray Waters, DVM, PhD, is a veterinary medical officer in the TB Research Project in the Infectious Bacterial Diseases of Livestock Research Unit at the National Animal Disease Center, Agricultural Research Service, United States Department of Agriculture (USDA), Ames, Iowa, and a collaborator/assistant professor of veterinary microbiology and preventive medicine at Iowa State University, Ames, Iowa. Dr. Mitchell V. Palmer, DVM, PhD, is a veterinary medical officer in the TB Research Project in the Infectious Bacterial Diseases of Livestock Research Unit at the National Animal Disease Center, Agricultural Research Service, USDA, Ames, Iowa, and a collaborator/assistant professor of veterinary pathology at Iowa State University, Ames, Iowa
| |
Collapse
|
5
|
Immune responses of bison and efficacy after booster vaccination with Brucella abortus strain RB51. CLINICAL AND VACCINE IMMUNOLOGY : CVI 2015; 22:440-7. [PMID: 25673305 DOI: 10.1128/cvi.00746-14] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Thirty-one bison heifers were randomly assigned to receive saline or a single vaccination with 10(10) CFU of Brucella abortus strain RB51. Some vaccinated bison were randomly selected for booster vaccination with RB51 at 11 months after the initial vaccination. Mean antibody responses to RB51 were greater (P < 0.05) in vaccinated bison after initial and booster vaccination than in nonvaccinated bison. The proliferative responses by peripheral blood mononuclear cells (PBMC) from the vaccinated bison were greater (P < 0.05) than those in the nonvaccinated bison at 16 and 24 weeks after the initial vaccination but not after the booster vaccination. The relative gene expression of gamma interferon (IFN-γ) was increased (P < 0.05) in the RB51-vaccinated bison at 8, 16, and 24 weeks after the initial vaccination and at 8 weeks after the booster vaccination. The vaccinated bison had greater (P < 0.05) in vitro production of IFN-γ at all sampling times, greater interleukin-1β (IL-1β) production in various samplings after the initial and booster vaccinations, and greater IL-6 production at one sampling time after the booster vaccination. Between 170 and 180 days of gestation, the bison were intraconjunctivally challenged with approximately 1 × 10(7) CFU of B. abortus strain 2308. The incidences of abortion and infection were greater (P < 0.05) in the nonvaccinated bison after experimental challenge than in the bison receiving either vaccination treatment. Booster-vaccinated, but not single-vaccinated bison, had a reduced (P < 0.05) incidence of infection in fetal tissues and maternal tissues compared to that in the controls. Compared to the nonvaccinated bison, both vaccination treatments lowered the colonization (measured as the CFU/g of tissue) of Brucella organisms in all tissues, except in retropharyngeal and supramammary lymph nodes. Our study suggests that RB51 booster vaccination is an effective vaccination strategy for enhancing herd immunity against brucellosis in bison.
Collapse
|
6
|
Fu K, Cheng Q, Liu Z, Chen Z, Wang Y, Ruan H, Zhou L, Xiong J, Xiao R, Liu S, Zhang Q, Yang D. Immunotoxicity assessment of rice-derived recombinant human serum albumin using human peripheral blood mononuclear cells. PLoS One 2014; 9:e104426. [PMID: 25099245 PMCID: PMC4123919 DOI: 10.1371/journal.pone.0104426] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2014] [Accepted: 07/08/2014] [Indexed: 11/19/2022] Open
Abstract
Human serum albumin (HSA) is extensively used in clinics to treat a variety of diseases, such as hypoproteinemia, hemorrhagic shock, serious burn injuries, cirrhotic ascites and fetal erythroblastosis. To address supply shortages and high safety risks from limited human donors, we recently developed recombinant technology to produce HSA from rice endosperm. To assess the risk potential of HSA derived from Oryza sativa (OsrHSA) before a First-in-human (FIH) trial, we compared OsrHSA and plasma-derived HSA (pHSA), evaluating the potential for an immune reaction and toxicity using human peripheral blood mononuclear cells (PBMCs). The results indicated that neither OsrHSA nor pHSA stimulated T cell proliferation at 1x and 5x dosages. We also found no significant differences in the profiles of the CD4(+) and CD8(+) T cell subsets between OsrHSA- and pHSA-treated cells. Furthermore, the results showed that there were no significant differences between OsrHSA and pHSA in the production of cytokines such as interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), interleukin (IL)-10 and IL-4. Our results demonstrated that OsrHSA has equivalent immunotoxicity to pHSA when using the PBMC model. Moreover, this ex vivo system could provide an alternative approach to predict potential risks in novel biopharmaceutical development.
Collapse
Affiliation(s)
- Kai Fu
- State Key Laboratory of Hybrid Rice and College of Life Sciences, Wuhan University, Wuhan, China
| | - Qin Cheng
- State Key Laboratory of Hybrid Rice and College of Life Sciences, Wuhan University, Wuhan, China
| | - Zhenwei Liu
- State Key Laboratory of Hybrid Rice and College of Life Sciences, Wuhan University, Wuhan, China
| | - Zhen Chen
- State Key Laboratory of Hybrid Rice and College of Life Sciences, Wuhan University, Wuhan, China
| | - Yan Wang
- Institute of Hydrobiology, Chinese Academy of Sciences, Analysis and Testing center, Wuhan, China
| | - Honggang Ruan
- Department of Immunology, College of Basic Medical Science, Wuhan University, Wuhan, China
| | - Lu Zhou
- Department of Immunology, College of Basic Medical Science, Wuhan University, Wuhan, China
| | - Jie Xiong
- Department of Immunology, College of Basic Medical Science, Wuhan University, Wuhan, China
| | - Ruijing Xiao
- Department of Immunology, College of Basic Medical Science, Wuhan University, Wuhan, China
| | - Shengwu Liu
- Department of Immunology, College of Basic Medical Science, Wuhan University, Wuhan, China
| | - Qiuping Zhang
- Department of Immunology, College of Basic Medical Science, Wuhan University, Wuhan, China
| | - Daichang Yang
- State Key Laboratory of Hybrid Rice and College of Life Sciences, Wuhan University, Wuhan, China
| |
Collapse
|
7
|
Efficacy of dart or booster vaccination with strain RB51 in protecting bison against experimental Brucella abortus challenge. CLINICAL AND VACCINE IMMUNOLOGY : CVI 2012; 19:886-90. [PMID: 22496493 DOI: 10.1128/cvi.00107-12] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
This study characterized the efficacy of the Brucella abortus strain RB51 vaccine in bison when delivered by single intramuscular vaccination (hand RB51), by single pneumatic dart delivery (dart RB51), or as two vaccinations approximately 13 months apart (booster RB51) in comparison to control bison. All bison were challenged intraconjunctivally in midgestation with 10(7) CFU of B. abortus strain 2308 (S2308). Bison were necropsied and sampled within 72 h of abortion or delivery of a live calf. Compared to nonvaccinated bison, bison in the booster RB51 treatment had a reduced (P < 0.05) incidence of abortion, uterine infection, or infection in maternal tissues other than the mammary gland at necropsy. Bison in single-vaccination treatment groups (hand RB51 and dart RB51) did not differ (P > 0.05) from the control group in the incidence of abortion or recovery of S2308 from uterine, mammary, fetal, or maternal tissues at necropsy. Compared to nonvaccinated animals, all RB51 vaccination groups had reduced (P < 0.05) mean colonization or incidence of infection in at least 2 of 4 target tissues, with the booster RB51 group having reduced (P < 0.05) colonization and incidence of infection in all target tissues. Our data suggest that booster vaccination of bison with RB51 enhances protective immunity against Brucella challenge compared to single vaccination with RB51 by hand or by pneumatic dart. Our study also suggests that an initial vaccination of calves followed by booster vaccination as yearlings should be an effective strategy for brucellosis control in bison.
Collapse
|